Drug intelligence / Profile preview

Ilodecakin (Renovo)

Development stage: Phase 2
Lead developer: Merck
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal

Overview

Prevascar is a therapeutic drug formulation of human recombinant Interleukin 10 (IL-10) developed for the prevention and reduction of scarring in the skin. It acts as an important modulator of the inflammatory response, resulting in improved scar appearance after wounding and surgery. Clinical trials have shown that Prevascar-treated wounds result in scars that are scored as improved by both subjects and clinicians. The drug has demonstrated safety and efficacy in Phase II clinical trials for scar prevention and reduction[3][5][7].

Brand names: Prevascar
Other names: PrevascarIlodecakinRecombinant IL-10 (scarring)Ilodecakin Renovo

Targets

IL10RA (Interleukin-10 Receptor)

Beyond the preview

Go deeper on Ilodecakin (Renovo).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ilodecakin (Renovo).

Explore the full profile